Welcome to our dedicated page for Acm Research SEC filings (Ticker: ACMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ACM Research’s wafer-cleaning and advanced-packaging systems sit at the heart of today’s most intricate chip fabs—yet the disclosures that explain how those tools drive revenue and margins stretch well past 200 pages. Finding segment sales to Chinese foundries, understanding megasonic R&D spend, or monitoring insider sales after export-control headlines can feel overwhelming. That’s why investors searching for “ACM Research SEC filings explained simply” start here.
Stock Titan applies AI-powered parsing to every document the moment it hits EDGAR. Whether you need the full ACM Research quarterly earnings report 10-Q filing, a line-by-line breakdown of the ACM Research annual report 10-K simplified, or ACM Research 8-K material events explained, our platform converts technical language into concise, decision-ready insights. Real-time alerts surface ACM Research Form 4 insider transactions, while side-by-side charts compare backlog, gross margin and regional revenue across periods—saving hours of manual cross-referencing.
Use cases are practical: track ACM Research executive stock transactions Form 4 before earnings, study wafer-cleaning tool demand swings through our ACM Research earnings report filing analysis, or verify board pay packages in the ACM Research proxy statement executive compensation section. All filing types—10-K, 10-Q, 8-K, S-8, Form 4—are covered with comprehensive, time-stamped updates. From megasonic-cleaning capacity additions to advanced-packaging revenue outlook, understanding ACM Research SEC documents with AI has never been easier.
ACM Research, Inc. (ACMR) reported that its operating subsidiary, ACM Research (Shanghai), Inc., which is listed on the STAR Market of the Shanghai Stock Exchange, filed a Record of November 2025 Investor Relations Activity with the Shanghai Stock Exchange. The exchange posted this record on November 19, 2025, and ACM has attached an unofficial English translation as Exhibit 99.1.
The company specifies that this information, including Exhibit 99.1, is being furnished rather than filed, meaning it is not subject to certain liability provisions of the U.S. securities laws and is not automatically incorporated by reference into other ACM Research filings.
ACM Research (ACMR) director Haiping Dun filed a Form 4 reporting a charitable-style transfer. On 11/12/2025, he made a gift of 755,090 shares of Class A common stock (transaction code G) at $0 to the Haiping Dun & Chi-Pin H Dun Revocable Trust, where he serves as co‑trustee and immediate family members are beneficiaries.
Following the transaction, reported holdings shifted to 0 shares direct and 755,090 shares indirect via the trust. This filing reflects a change in form of ownership, not an open-market sale.
ACM Research (ACMR): insider Form 4 shows option exercises and sales. An officer reported exercising 15,000 stock options at $5.60 on 11/12/2025 and another 15,000 at $5.60 on 11/13/2025. On the same dates, 15,000 shares were sold at $32.76 and 15,000 shares at $33.77, respectively.
The sales were made under a Rule 10b5-1 trading plan adopted on 08/13/2025. Following each day’s transactions, the filing lists 50,001 shares beneficially owned directly. The exercised options were fully vested and carry an expiration date of 04/22/2029.
ACM Research (ACMR) filed its Q3 2025 10‑Q, reporting stronger results. Revenue was $269,160 for the quarter versus $203,976 a year ago, with diluted EPS of $0.52. For the nine months, revenue reached $656,879 and diluted EPS was $1.26. Net income attributable to ACM Research, Inc. was $35,889 in Q3.
Gross profit was $113,149 on cost of revenue of $156,011. Operating expenses rose to $84,226, led by higher R&D and SG&A. Cash and cash equivalents were $1,058,909 as of September 30, 2025. Operating cash flow for the nine months was $(44,244), while financing activities provided $738,115, including $622,964 of net proceeds from an issuance of shares by ACM Shanghai.
In September 2025, ACM Shanghai issued 38.6 million ordinary shares in a private offering, lowering ACM Research’s interest in ACM Shanghai from 81.1% to 74.6% at September 30, 2025. Shares outstanding were 59,854,640 Class A and 5,021,811 Class B as of November 3, 2025.
ACM Research, Inc. furnished an 8-K announcing it issued a press release with financial results for the third quarter of 2025. The press release, dated November 5, 2025, is included as Exhibit 99.1 and incorporated by reference.
The disclosure was made under Item 2.02 (Results of Operations and Financial Condition) and is designated as furnished, not filed under the Exchange Act. The filing also lists the company’s Class A common stock trading on Nasdaq under the symbol ACMR.
ACM Research (ACMR) Form 4: CEO, President and Director David H. Wang reported vesting and acquisition of 545,400 stock options at an exercise price of $7.36 on October 27, 2025, from a 2020 performance grant. These options are now exercisable and expire on March 19, 2030.
The vesting occurred after the company’s market capitalization reached $2,553,383,586 under the grant’s formula; remaining tranches vest if market cap reaches $3,553,383,586. Indirect beneficial holdings disclosed include 620,001 shares (Wang‑Chen Family Living Trust), 180,000 (Family Irrevocable Trust for Wang Children), 100,002 (spouse), and 45,837 (daughter).
BlackRock, Inc. reported beneficial ownership of 7,420,308 shares of ACM Research, Inc. Class A stock, representing 12.6% of the class. The report, filed as a Schedule 13G/A and signed on 10/02/2025, discloses sole voting power over 7,296,615 shares and sole dispositive power over 7,420,308 shares as of the 09/30/2025 event date. The filing notes that iShares Core S&P Small-Cap ETF holds more than 5% of ACMR common stock. The Schedule 13G states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
David H. Wang, CEO and Director of ACM Research, Inc. (ACMR), exercised 130,000 vested stock options by net exercise on 09/08/2025 at an exercise price of $1 per share. The filing shows the option was fully vested and the net exercise closed on that date, resulting in 610,002 shares held directly after the transaction. The report also discloses indirect holdings: 100,002 shares held by Jing Chen (his wife), 45,837 by his daughter Sophia Wang, 180,000 by a family trust for his children, and 620,001 by the Wang-Chen Family Living Trust. The Form 4 was signed by an attorney-in-fact on 09/30/2025.
FAQ
What is the current stock price of Acm Research (ACMR)?
What is the market cap of Acm Research (ACMR)?
